KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Net Cash Flow (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Net Cash Flow for 9 consecutive years, with -$301.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Cash Flow fell 3620.36% year-over-year to -$301.4 million, compared with a TTM value of -$349.8 million through Dec 2025, down 6643.25%, and an annual FY2025 reading of -$16.3 million, down 213.34% over the prior year.
  • Net Cash Flow was -$301.4 million for Q4 2025 at Biocryst Pharmaceuticals, down from -$45.2 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $18.0 million in Q3 2024 and bottomed at -$301.4 million in Q4 2025.
  • Average Net Cash Flow over 3 years is -$45.8 million, with a median of -$7.1 million recorded in 2023.
  • The sharpest move saw Net Cash Flow skyrocketed 304.95% in 2024, then tumbled 3620.36% in 2025.
  • Year by year, Net Cash Flow stood at -$40.6 million in 2023, then surged by 121.11% to $8.6 million in 2024, then crashed by 3620.36% to -$301.4 million in 2025.
  • Business Quant data shows Net Cash Flow for BCRX at -$301.4 million in Q4 2025, -$45.2 million in Q3 2025, and -$3.3 million in Q2 2025.